Dyadic International Inc (NASDAQ: DYAI) is in an interesting position, being one of the very few names in the anti-Covid space that offer a new path that isn’t simply a reproduction or tie-in to the big pharma game right now.
DYAI has a new approach that isn’t new-age quote-unquote “science”, but a powerful new potential solution that holds the capacity to possibly become better able to deal with new variants and even possibly better able to drive cheap and efficient production capable of vaccinating the world compared to others such as: Astrazeneca (NASDAQ: AZN), Moderna Inc. (NASDAQ: MRNA), Novavax Inc. (NASDAQ: NVAX), Pfizer (NYSE: PFE), Johnson & Johnson (NYSE: NJ), and Biontech (NASDAQ: BNTX).
The company has now started to move toward collaborations that could produce the next major breakthrough in fighting Covid-19 over the long term, including vaccines that cover Covid-19 variants. In fact, DYAI believes it can produce trivalent and quadrivalent Covid-19 vaccines – ie a single vaccine that can cover three or even four variants of the virus simultaneously.
According to materials published by Dyadic International Inc (NASDAQ :DYAI), the C1 microorganism that forms the basis of its technology enables the development and large-scale manufacture of low-cost proteins and has the potential to be further developed into a safe and efficient expression system that may help speed up the development of biologic vaccines and drugs at commercial scales, while lowering production costs and improving performance at the same time.
There is still a lot of testing to be done. But the building blocks are potentially in place, and the company is moving forward with data-gathering activities that may produce game-changing results.
Dyadic’s Technology and Production Vectors
The technological breakthrough in play from DYAI has, most centrally, to do with vaccine production and the biological technology required to produce vaccines in large quantities.
Proteins associated with vaccine production are produced through a “vector”. The baculovirus–insect cell expression system is a commonly used vector and has been extensively utilized for the production of many recombinant proteins and commercial vaccines.
For example, for the production host of antigens for the Schmallenberg virus (SBV), we have comparative data. SBV antigens have been produced through both baculovirus–insect cell expression systems and through DYAI’s fungal system. As it turns out, the SBV antigen from C1 produced 300 times greater yields than the SBV antigen from baculovirus and was more stable.
Additionally, the C1 SBV antigen was shown to be safe and very effective (Full Protection) in protecting cattle and mice from the SBV.
DYAI believes its system could represent a breakthrough on a potentially significant scale as a biopharmaceutical gene expression platform. The key differentiating factor is that the DYAI system is based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1.
The C1 microorganism is technically a fungal body, which differentiates its platform from other major vaccine programs.
Based on its SBV results, additional fully funded animal trials are continuing in 2021 with C1 expressed antigens for SBV and RVFV and to generate additional safety and efficacy data. The company is also beginning to test its platform as a system for generating results in the battle against Covid-19.
Why it Matters
According to Bloomberg, enough doses have now been administered to fully vaccinate 8.6% of the global population—but the distribution has been lopsided. Countries and regions with the highest incomes are getting vaccinated about 25 times faster than those with the lowest.
But new and potentially deadly variants can emerge anywhere and still end up taking over the world.
New variants are popping up almost weekly, it seems. Eventually, one will emerge that falls outside the efficacy range of our currently approved vaccines. The more people on the planet that remain unvaccinated, the faster such a threat will become a manifest reality.
In other words, either we find a faster, cheaper means of reaching vaccine-induced herd immunity, or we may be headed back into a new chapter in an ongoing pandemic crisis.
If DYAI’s CI-based platform is able to prove itself as a solution that can produce more vaccine doses at a lower cost without sacrificing efficacy, then it could represent an important breakthrough that changes the course toward a less vulnerable path.DISCLAIMER: EDM Media LLC (EDM), is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. EDM is NOT affiliated in any manner with any company mentioned herein. EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell or offer to buy any security. EDM’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. EDM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed EDM has been compensated six thousand dollars for news coverage of the current press releases issued by Dyadic International Inc (NASDAQ: DYAI) by a third party.
EDM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.
EDM Media LLC